Simulect and Kidney fibrosis - a phase IV clinical study of FDA data

Summary:

Kidney fibrosis is reported as a side effect among people who take Simulect (basiliximab), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Tacrolimus, and have Immunodeficiency disorders.

The phase IV clinical study analyzes which people have Kidney fibrosis when taking Simulect. It is created by eHealthMe based on reports of 3,859 people who have side effects when taking Simulect from the FDA, and is updated regularly.

What is Simulect?

Simulect has active ingredients of basiliximab. eHealthMe is studying from 3,861 Simulect users. Check the latest studies of Simulect.

What is Kidney fibrosis?

Kidney fibrosis (excess fibrous connective tissue in kidney) is found to be associated with 188 drugs and 363 conditions by eHealthMe. Check the latest studies of Kidney fibrosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

3,859 people reported to have side effects when taking Simulect.
Among them, 31 people (0.8%) have Kidney fibrosis.

Among these 31 people:

How long have people been on Simulect when they have Kidney fibrosis? *

What is the gender of people who have Kidney fibrosis when taking Simulect? *

female: 37.93 %
male: 62.07 %

What is the age of people who have Kidney fibrosis when taking Simulect? *

What are other drugs people take besides Simulect? *

What are other side effects people have besides Kidney fibrosis? *

Renal Tubular Atrophy (wasting of kidney tubules): 23 people, 74.19%
Kidney Transplant Rejection: 12 people, 38.71%
Complications Of Transplanted Kidney: 11 people, 35.48%
Blood Creatinine Increased: 8 people, 25.81%
Diarrhea: 7 people, 22.58%
Interstitial Nephritis (inflammation of the kidney): 6 people, 19.35%
Thrombocytopenia (decrease of platelets in blood): 6 people, 19.35%
Glomerulosclerosis (a hardening of the glomerulus in the kidney): 5 people, 16.13%
Glomerulonephritis (a group of conditions that affect parts of the kidneys called glomeruli): 5 people, 16.13%
Atherosclerosis (disorder of the arteries): 4 people, 12.90%

What are the existing conditions these people have? *

Immunodeficiency Disorders: 6 people, 19.35%
Allergies: 2 people, 6.45%
Growth Of Eyelashes: 1 person, 3.23%
Bleeding Disorders: 1 person, 3.23%
Bone Disorder: 1 person, 3.23%
Dyslipidaemia (abnormal amount of lipids): 1 person, 3.23%
Dyspnea (difficult or laboured breathing): 1 person, 3.23%
Eye Disorder: 1 person, 3.23%
Gastric Ulcer (stomach ulcer): 1 person, 3.23%
Gout (uric acid crystals building up in the body): 1 person, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Simulect and have Kidney fibrosis?

- Check whether Kidney fibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Simulect:

Simulect (3,861 reports)

Kidney fibrosis treatments and more:

Kidney fibrosis (1,874 reports)

Browse all side effects of Simulect:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Kidney fibrosis:

Kidney fibrosis (188 drugs)

Browse all the conditions that are associated with Kidney fibrosis:

Kidney fibrosis (363 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on basiliximab (the active ingredients of Simulect) and Simulect (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.